Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6Clo monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the chemokine CX3CL1 was upregulated in both human and murine tumors following VEGF signaling blockade, resulting in recruitment of CX3CR1+Ly6Clo monocytes into the tumor. We also found that treatment with VEGFA reduced expression of CX3CL1 in endothelial cells in vitro. Intravital microscopy revealed that CX3CR1 is critical for Ly6Clo monocyte transmigration across the endothelium in murine CRC tumors. Moreover, Ly6Clo monocytes recruit Ly6G+ neutrophils via CXCL5 and produce IL-10, which inhibits adaptive immunity. Preventing Ly6Clo monocyte or Ly6G+ neutrophil infiltration into tumors enhanced inhibition of tumor growth with anti-VEGFR2 therapy. Furthermore, a gene therapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6Clo monocyte recruitment and improved outcome of anti-VEGFR2 therapy in mouse CRCs. Our study unveils an immunosuppressive function of Ly6Clo monocytes that, to our knowledge, has yet to be reported in any context. We also reveal molecular mechanisms underlying antiangiogenic treatment resistance, suggesting potential immunomodulatory strategies to enhance the long-term clinical outcome of anti-VEGF therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“emerging data suggest that immunosuppression, in turn, contributes to resistance to antiangiogenesis treatments37–39,41”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“In mouse models of CRC, high-dose anti-VEGF treatment can also result in the recruitment of immunosuppressive, nonclassical, lymphocyte antigen 6C (Ly6C)low monocytes that also confer resistance to anti-VEGF therapy, thus setting up a vicious cycle38,39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“These cells display a high level of CX3CR1, while Ly6Chi monocytes and Ly6G+ neutrophils (hereafter referred to as neutrophils) express CCR2 and CXCR2, respectively (25, 39, 44) (Supplemental Figure 2B).”
BackgroundBlood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties
Geissmann, F., Jung, S., & Littman, D. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00174-2 · Cited by 3,391
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“, CX3CR1 on Ly6Clo monocytes, CCR2 on Ly6Chi monocytes) (32, 59) (Supplemental Figure 2B).”
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 2×
“Cx3cr1gfp/gfp mice were originally provided by Dan R. Littman (New York University School of Medicine, New York, New York, USA) (51).”
BackgroundNahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.-L., Libby, P., Weissleder, R., & Pittet, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070885 · Cited by 2,300
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Monitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior
Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., Cumano, A., Lauvau, G., & Geissmann, F. (2007) · Science · doi:10.1126/science.1142883 · Cited by 1,973
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 2×
“org Volume 127 Number 8 August 2017 Introduction Angiogenesis is a hallmark of cancer (1).”
BackgroundSelf-citationThe cellular and molecular origin of tumor-associated macrophages
Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., Pamer, E. G., & Li, M. O. (2014) · Science · doi:10.1126/science.1252510 · Cited by 1,393
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 1×
“We used DC101, a monoclonal antibody against VEGFR2, to inhibit angiogenesis (34).”
MethodSelf-citationHistory of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 2×
“, tumor-associated macrophages[TAMs]) subsequently regulates the activity of cytotoxic T cells in breast cancer models and that depletion of the cytotoxic T cells using anti-CD8 neutralizing antibody abrogated the effect of TAM modulation (63).”
BackgroundSelf-citationTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 4×
“Emerging data show that the immune system also plays a critical role in refractoriness to antiangiogenic therapy (13, 23, 24).”
BackgroundResultInfluentialNr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal
Carlin, L. M., Stamatiades, E. G., Auffray, C., Hanna, R. N., Glover, L., Vizcay-Barrena, G., Hedrick, C. C., Cook, H. T., Diebold, S., & Geissmann, F. (2013) · Cell · doi:10.1016/j.cell.2013.03.010 · Cited by 768
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 1×
“Recently, 2 studies revealed that inhibition of granulocyte recruitment into tumors improves the efficacy of the immune checkpoint blockade (35, 41).”
BackgroundFong, A. M., Robinson, L. A., Steeber, D. A., Tedder, T. F., Yoshie, O., Imai, T., & Patel, D. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.8.1413 · Cited by 679
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
D’Angelo, S. P., Larkin, J., Sosman, J. A., Lebbé, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J. C., Hodi, F. S., Lorigan, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9258 · Cited by 650
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 630
Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S., Van Ginderachter, J. A., Tamagnone, L., & Mazzone, M. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.007 · Cited by 629
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight
Dahlman, J. E., Barnes, C., Khan, O. F., Thiriot, A., Jhunjunwala, S., Shaw, T. E., Xing, Y., Sager, H. B., Sahay, G., Speciner, L., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.84 · Cited by 592
Self-citationInactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Self-citationMET is required for the recruitment of anti-tumoural neutrophils
Finisguerra, V., Di Conza, G., Di Matteo, M., Serneels, J., Costa, S., Thompson, A. A. R., Wauters, E., Walmsley, S., Prenen, H., Granot, Z., et al. (2015) · Nature · doi:10.1038/nature14407 · Cited by 492
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival
Landsman, L., Bar-On, L., Zernecke, A., Kim, K.-W., Krauthgamer, R., Shagdarsuren, E., Lira, S. A., Weissman, I. L., Weber, C., & Jung, S. (2009) · Blood · doi:10.1182/blood-2008-07-170787 · Cited by 490
Hu, Y.-L., DeLay, M., Jahangiri, A., Molinaro, A. M., Rose, S. D., Carbonell, W. S., & Aghi, M. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3831 · Cited by 483
Patrolling monocytes control tumor metastasis to the lung
Hanna, R. N., Cekic, C., Sag, D., Tacke, R., Thomas, G. D., Nowyhed, H., Herrley, E., Rasquinha, N., McArdle, S., Wu, R., et al. (2015) · Science · doi:10.1126/science.aac9407 · Cited by 480
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477
Kim, J. E., Patel, M. A., Mangraviti, A., Kim, E. S., Theodros, D., Velarde, E., Liu, A., Sankey, E. W., Tam, A., Xu, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1535 · Cited by 461
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 1×
“Unlike Gr1+ monocytes and granulocytic cells (6, 23, 24), Ly6Clo monocytes represent a distinct cell population that has never been studied for its role in conferring resistance to anti-VEGF therapy.”
BackgroundTumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388
Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Sitohy, B., Nagy, J. A., & Dvorak, H. F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3406 · Cited by 360
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., Carlson, M. A., Cuevas, C., Simmons, R. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Gut · doi:10.1136/gutjnl-2013-306271 · Cited by 331
Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo
Tannous, B. A. (2009) · Nature Protocols · doi:10.1038/nprot.2009.28 · Cited by 303
Ratcliffe, M. J., Sharpe, A., Midha, A., Barker, C., Scott, M., Scorer, P., Al-Masri, H., Rebelatto, M. C., & Walker, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2375 · Cited by 301
Surgical implantation of an abdominal imaging window for intravital microscopy
Ritsma, L., Steller, E. J. A., Ellenbroek, S. I. J., Kranenburg, O., Borel Rinkes, I. H. M., & van Rheenen, J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.026 · Cited by 279
In vivo structure/function and expression analysis of the CX3C chemokine fractalkine
Kim, K.-W., Vallon-Eberhard, A., Zigmond, E., Farache, J., Shezen, E., Shakhar, G., Ludwig, A., Lira, S. A., & Jung, S. (2011) · Blood · doi:10.1182/blood-2011-04-348946 · Cited by 277
Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258 · cited 1×
“Indeed, the therapeutic dose of bevacizumab currently used in the clinic is often considered as a high dose (69), which is comparable to the dose we used in our study (maximum effective dose).”
MethodSelf-citationRole of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Molecular Uncoupling of Fractalkine-mediated Cell Adhesion and Signal Transduction
Haskell, C. A., Cleary, M. D., & Charo, I. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10053 · Cited by 235
Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S. C., Rao, S. S., Qian, J., Hailemichael, Y., Nurieva, R., Dwyer, K. C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3560 · Cited by 233
Endoscopic Time-Lapse Imaging of Immune Cells in Infarcted Mouse Hearts
Jung, K., Kim, P., Leuschner, F., Gorbatov, R., Kim, J. K., Ueno, T., Nahrendorf, M., & Yun, S. H. (2013) · Circulation Research · doi:10.1161/circresaha.111.300484 · Cited by 187
Self-citationPalmer, G. M., Fontanella, A. N., Shan, S., Hanna, G., Zhang, G., Fraser, C. L., & Dewhirst, M. W. (2011) · Nature Protocols · doi:10.1038/nprot.2011.349 · Cited by 168
Complexity and challenges in defining myeloid-derived suppressor cells
Damuzzo, V., Pinton, L., Desantis, G., Solito, S., Marigo, I., Bronte, V., & Mandruzzato, S. (2015) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21206 · Cited by 165
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
Self-citationIntertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158
Morari, J., Anhe, G. F., Nascimento, L. F., de Moura, R. F., Razolli, D., Solon, C., Guadagnini, D., Souza, G., Mattos, A. H., Tobar, N., et al. (2014) · Diabetes · doi:10.2337/db13-1495 · Cited by 147
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 147
In vivo wide-area cellular imaging by side-view endomicroscopy
Kim, P., Chung, E., Yamashita, H., Hung, K. E., Mizoguchi, A., Kucherlapati, R., Fukumura, D., Jain, R. K., & Yun, S. H. (2010) · Nature Methods · doi:10.1038/nmeth.1440 · Cited by 143
Self-citationColorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131 · cited 1×
“Some reports show that low doses of anti-VEGF therapy can induce vascular normalization and improve antitumor immunity (63, 64).”
BackgroundVascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption
Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., Lee, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.010 · Cited by 131
Chung, E., Yamashita, H., Au, P., Tannous, B. A., Fukumura, D., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008316 · Cited by 100
Self-citationImmune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
Zhang, Y., Davis, C., Ryan, J., Janney, C., & Peña, M. M. O. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9591-8 · Cited by 67
Myeloid cells in tumor inflammation
Schmid, M. C., & Varner, J. A. (2012) · Vascular Cell · doi:10.1186/2045-824x-4-14 · Cited by 65
Kirkpatrick, N. D., Chung, E., Cook, D., Han, X., Gruionu, G., Liao, S., Munn, L. L., Padera, T. P., Fukumura, D., & Jain, R. K. (2012) · IntraVital · doi:10.4161/intv.21557 · Cited by 56
Self-citationTriglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1low Monocytes
Saja, M. F., Baudino, L., Jackson, W. D., Cook, H. T., Malik, T. H., Fossati‐Jimack, L., Ruseva, M. M., Pickering, M. C., Woollard, K. J., & Botto, M. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.020 · Cited by 45
Morimoto‐Tomita, M., Ohashi, Y., Matsubara, A., Tsuiji, M., & Irimura, T. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-3585-0 · Cited by 44
Milosevic, M., Townsley, C. A., Chaudary, N., Clarke, B. A., Pintilie, M., Fan, S., Glicksman, R., Haider, M. A., Kim, S., MacKay, H. J., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.09.009 · Cited by 37
Escape Mechanisms from Antiangiogenic Therapy: An Immune Cell’s Perspective
Rivera, L. B., Pandika, M. M., & Bergers, G. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_4 · Cited by 12
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“, 2017) or inhibiting adaptive immunity (Jung et al., 2017).”
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationCassetta, L., Fragkogianni, S., Sims, A. H., Swierczak, A., Forrester, L. M., Zhang, H., Soong, D. Y. H., Cotechini, T., Anur, P., Lin, E. Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.009 · Cited by 920
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Self-citation
Metadata
- Authors
- Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., Yun, S. H., Langer, R., Anderson, D. G., Padera, T. P., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Duke Medical Center (US)
- Harvard–MIT Division of Health Sciences and Technology (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-07-10
- Volume
- 127
- Issue
- 8
- Pages
- 3039-3051
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531423
- OpenAlex
- W2726768474
- Cited by
- 164
- References
- 75
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 13 · 2023: 10 · 2022: 28 · 2021: 26 · 2020: 25 · 2019: 20 · 2018: 16 · 2017: 6
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- National Institutes of Health (NIH DP2, W81XWH, 1dp2od008780-01, CA126642, CA080124)
- Harvard School of Engineering and Applied Sciences
- National Cancer Institute (CA096915, W81XWH-10-1-0016, R01CA096915, P01CA080124, R00CA137167, R01CA126642, R35CA197743, R01CA208205, R01CA204028)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fractalkine, CX3CR1, anti-VEGF therapy resistance, colorectal cancer, immunosuppression, neutrophil recruitment, CXCL5, IL-10, endothelial cells, monocyte transmigration, siRNA gene therapy, nanoparticle delivery, tumor microenvironment
- MeSH terms
- Intravital Microscopy, CX3C Chemokine Receptor 1, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Agents, Humans, Immunosuppression Therapy, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Monocytes, Neoplasms, Neutrophils, Up-Regulation, Drug Resistance, Neoplasm, Receptors, Chemokine, RNA, Small Interfering, Vascular Endothelial Growth Factor Receptor-2, Cell Line, Tumor, Mice, Nanoparticles, Chemokine CX3CL1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.